Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 8/20 | 0.69 |
| ▸ | KDR | P35968 | 5/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | KIT | P10721 | 1/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869713 | 0.87 | ROCK2 (0.56) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL4002520 | 0.81 | ALDH1A1 (0.52) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL4002529 | 0.81 | ALDH1A1 (0.52) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL8213573 | 0.80 | TEK (0.55) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL643424 | 0.78 | ALDH1A1 (1.00) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL29898482 | 0.78 | ALDH1A1 (1.00) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL14003520 | 0.78 | TEK (0.51) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL4876359 | 0.77 | ROCK2 (0.71) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL4871872 | 0.77 | ROCK2 (0.48) | TEKKDREPHB4EGFRPDGFRB | |
| SCHEMBL4877251 | 0.75 | TEK (0.57) | TEKKDREPHB4EGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | TEK 2388/4885KDR 919/4885EPHB4 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.